Therapeutic | Mirzotamab |
Target | CD276 |
Heavy Chain | EVQLQESGPGLVKPSETLSLTCAVTGYSITSGYSWHWIRQFPGNGLEWMGYIHSSGSTNYNPSLKSRISISRDTSKNQFFLKLSSVTAADTAVYYCAGYDDYFEYWGQGTTVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQKPGKSPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFAEYFCQQYNWYPFTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-I |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2019 |
INN Year Recommended | None |
Companies Involved | AbbVie |
Conditions Approved | na |
Conditions Active | Haematological malignancies, Solid tumours |
Conditions Discontinued | na |
Notes |